The potency of alpha-humulene as HER-2 inhibitor by molecular docking
Pharmacy Reports · 2022
DOI: 10.51511/pr.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Reports, 2022. Verfasst von I Made Harimbawa Putra und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kementerian Riset, Teknologi dan Pendidikan Tinggi.
Abstract (Originalsprache)
HER-2 overexpression is present in approximately 20% of breast cancer. This research aims to study the interactions of α-humulene to HER-2 protein by using in silico molecular docking. The experiment was carried out by HER-2 protein preparation (PDB ID 3PP0), docking validation, α-humulene optimization, and α-humulene docking. The results showed that α-humulene had binding energy of -7.50 kcal/mol, Van der Waals binding energy of -7.48 kcal/mol, and electrostatic energy of -0.02 kcal/mol. α-Humulene is potential as anti-breast cancer towards HER-2 in silico.
Förderung
- Kementerian Riset, Teknologi dan Pendidikan Tinggi
Zitieren
APA
Putra, I. M. H., Pratama, I. P. A. A. C., Putra, K. D. A., Pradnyaswari, G. A. D., & Laksmiani, N. P. L. (2022). The potency of alpha-humulene as HER-2 inhibitor by molecular docking. Pharmacy Reports. https://doi.org/10.51511/pr.19
Vancouver
Putra IMH, Pratama IPAAC, Putra KDA, Pradnyaswari GAD, Laksmiani NPL. The potency of alpha-humulene as HER-2 inhibitor by molecular docking. Pharmacy Reports. 2022. doi:10.51511/pr.19
BibTeX
@article{Putra2022,
author = {Putra, I Made Harimbawa and Pratama, I Putu Ari Anggara Catur and Putra, Komang Dian Aditya and Pradnyaswari, G. A. Desya and Laksmiani, Ni Putu Linda},
title = {The potency of alpha-humulene as HER-2 inhibitor by molecular docking},
journal = {Pharmacy Reports},
year = {2022},
doi = {10.51511/pr.19}
}
EUVIMED